Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Arm, Open-Label, Phase 2 Study of Melflufen in Combination With Dexamethasone in Patients With Relapsed Refractory Multiple Myeloma Who Are Refractory to Pomalidomide and/or an Anti-CD38 Monoclonal Antibody

NCT02963493 is registered in ClinicalTrials.gov with Oncopeptides AB as lead sponsor.

NCT NCT02963493
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02963493 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Arm, Open-Label, Phase 2 Study of Melflufen in Combination With Dexamethasone in Patients With Relapsed Refractory Multiple Myeloma Who Are Refractory to Pomalidomide and/or an Anti-CD38 Monoclonal Antibody
Lead sponsor
Oncopeptides AB
Phase
Phase 2
Overall status
Completed
Start date
December 28, 2016
Completion date
November 16, 2021
Enrollment
157 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma